The biotech firm reported a Q2 GAAP loss of $0.45 per share, missing expectations as cash reserves extend runway into early 2027.
Acumen Pharmaceuticals posted a second-quarter GAAP loss of $0.45 per share, falling short of estimates by $0.12. The wider-than-expected loss reflects ongoing clinical and operational costs as the company advances its pipeline.
Cash and equivalents totaled $110.2 million as of June 30, 2026, a position management expects will fund activities into early 2027. The figure provides a clearer timeline for investors amid the firm’s development phase.
No immediate market reaction was disclosed in the release.